1053719-22-4

Basic information

• Product Name: 2-{2-{-2{-2(benzyloxy)propanoyloxy}propanoyloxy}propanoyloxy}propanoicacid-tert.butylester
• Synonyms: 2-{2-{-2{-2(benzyloxy)propanoyloxy}propanoyloxy}propanoyloxy}propanoicacid-tert.butylester
• CAS NO: 1053719-22-4
• Molecular Weight: 452.502
• Mol File: 1053719-22-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-{2-{-2{-2(benzyloxy)propanoyloxy}propanoyloxy}propanoyloxy}propanoicacid-tert.butylester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{2-{-2{-2(benzyloxy)propanoyloxy}propanoyloxy}propanoyloxy}propanoicacid-tert.butylester(1053719-22-4)
• EPA Substance Registry System: 2-{2-{-2{-2(benzyloxy)propanoyloxy}propanoyloxy}propanoyloxy}propanoicacid-tert.butylester(1053719-22-4)

Safety Data

• Hazardous Substances Data: 1053719-22-4(Hazardous Substances Data)

Upstream product

• 1053718-97-0 2-{2-(benzyloxy)-propanoyloxy}propanoic acid 
• 13650-70-9 (+)-tert-butyl D-lactate 
• 33106-32-0 (S)-2-(benzyloxy)propanoic acid 

Relevant articles and documents

Lactic acid oligomers (OLAs) as prodrug moieties

In this paper we propose the use of lactic acid oligomers (OLAs) as prodrug moieties. Two synthetic approaches are presented, on the one hand a non selective oligomerisation of lactic acid and on the other hand a block synthesis to tetramers of lactic acid. Dimers of lactic acid were investigated with respect to their plasma stability and their adsorption to albumine. Ibuprofen was chosen as the first drug for OLAylation. The ester 19 of LA(1)-ibuprofen was evaluated with respect to the degradation to human plasma and the adsorption to albumine. All results indicate that lactic acid oligomers are promising prodrug moieties.